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Abstract Investigation of lung clearance of 99mTc-labelled diethylene triamine penta-acetic acid (DTPA) in smoking
sarcoid patients has been impeded bydifficulties to differ betweenpathologyof clearance kinetics caused by sarcoidosis
andbysmoking.This studyexplores thekineticsof lungclearance of 99mTc-DTPAin15 current smokerswithintrathoracic
sarcoidosis. The results are compared with findings from 16 healthy smokers. Measurements of lung clearance over
180min, i.e. longer than usual, revealed in 11 of the sarcoid patients a bi-exponential lung clearance course, which is
pathologic. All healthy smokers also showed a bi-exponential lung clearance. In the analysis of the bi-exponential curve
aninitial fast, anda slowclearance componentcouldbe separated.The smokerswith sarcoidosishada significantlyhigher
eliminationrateofthe slowcomponentthanthehealthysmokers.Thus, analysisofthelatepartofthelungclearance curve
may be rewarding in smoking sarcoid patients.The study shows that lung clearance of 99mTc-DTPAmay be a method
useful also in smokingpatientswith sarcoidosis.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1285, available online athttp://www.idealibrary.comon
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Lung clearance of 99mTc-DTPA has during the last 20
years been used for studies of the permeability of the al-
veolo-capillary barrier to small water-soluble sub-
stances. The normal clearance course is mono-
exponential. An increasedrate of clearance is seen in dif-
ferent pulmonary diseases as well as in healthy smokers
(1). Interstitial lung disease and smokingmay cause an ad-
ditive e¡ect on the increase of the clearance rate (2).
Whenmaking recordings for 3h, i.e. considerably longer
than the usual period of10^30min after inhalation, a bi-
exponential lung clearancemaybe disclosed, e.g. in some
patients with sarcoidosis and in healthy smokers (3,4).
Conventional measurements of lung clearance in smok-
ing patients with sarcoidosis have been hampered by
the presence of the qualitatively similar disturbances of
lung clearance of 99mTc-DTPA in interstitial lung disease
and in smoking.To avoid confounding in£uence of smok-Received 2 December 2001, accepted in revised form 20 December
2001.
Correspondence should be addressed to:Dr Ingela BrFdvik,
Department of Respiratory Medicine and Allergology,University
Hospital of Lund, SE-22185 Lund, Sweden.Fax: +46 46146793;
E-mail: ingela.brFdvik@skane.seing on the results, previous studies of lung clearance of
99mTc-DTPA in sarcoidosis have been performed in
never-smokers or in patients at least not being current
smokers (5^8).
The aim of this study was to explore the kinetics of
lung clearance of 99mTc-DTPAmeasured over180min in
smoking patients with radiological signs of intrathoracic
sarcoidosis and to compare the kinetics with ¢ndings in
healthy smokers.Moreover, in six patients data are pre-
sented from a repeat lung clearance measurement per-
formed after1year.
MATERIALANDMETHODS
Study subjects
Fifteen current smokers with radiological signs of in-
trathoracic sarcoidosis were studied. All but two of the
patients belonged to a series of consecutive sarcoidosis
patients referred to the Department of Respiratory
Medicine and Allergology, University Hospital of Lund.
The sarcoiddiseasewas either newlydiagnosed, or there
was a relapse. In two patients earlier chest radiographs
indicated a disease duration of more than 2 years. In an-
other three patients the disease duration could not be
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duration variedbetween 4 and15months as judged from
clinical data and chest radiographs. In all patients a posi-
tive Kveim test or other kind of tissue biopsy supported
the diagnosis. At the time of inclusion into the study ¢ve
of the patients were asymptomatic, six patients had
slight cough and/or breathlessness and the others suf-
fered frommild constitutional symptoms or skin lesions.
At inclusion nonewas on steroid treatment, butone wo-
man had earlier received peroral steroids because of re-
spiratory symptoms.Therewere ¢vewomen and10men.
Their mean age was 37717 years. Their smoking habits
showed awide range (Table1). In onepatient information
about the exact smoking history was lost.
The standard chest radiographs in posteroanterior
and lateral projections obtained at inclusion were later
reviewed by a senior radiologist blinded to other data.
The classi¢cation system emphasizes parenchymal
changes (9). Stage I implies lymph node enlargement
without parenchymal changes, stage II interstitial par-
enchymal changes irrespective of node enlargement and
stage III signs of ¢brosis apart from other abnormalities.
The degree of a change was scored as mild¼1, moder-
ate¼2 and extensive¼3. Six patients showed stage I
radiographs, seven had stage II appearance and two pa-
tients had stage III radiographs. The interstitial changes
were in ¢ve patients given score1, in one patient score 2
and in three patients score 3. For signs of ¢brosis one of
the patients with stage III disease was given score 1, and
the other stage III patient score 2.
Six of the patients, i.e. four stage I patients, one stage
II and one stage III patient were reinvestigated after 1TABLE 1. Clinical characteristics and spirometric ¢nd-
ings at inclusion
Sarcoidosis
n¼15
Healthy
smokers
n¼16
Age (years, mean7SD) 37717 40712
Steroid treatment
current n¼ 0
previous n¼ 1
Tobacco consumption
pack years
(median, range)
14,0.5^38 16,4^39
currentnumber
of cigarettes/
day (median, range) 13, 5^20 15, 5^20
Chest radiography
Stage I n¼ 6
Stage II n¼ 7
Stage III n¼ 2
VC %pred (median, range) 96, 57^121 94,67^122
FEV1%pred (median, range) 92,65^121 98,62^115year. After inclusion the latter twopatients receivedper-
oral steroid treatment beginning with 32mg of methyl-
prednisolone, which was after 2 months tapered to
16mg and after 6 months to 8mg.At follow-up in two
stage I patients the chest radiographs were normalized.
The sole stage II patient showed signs of ¢brosis.
The 16 healthy smokers have been characterized be-
fore (3).Their tobacco consumption is shown inTable1.
The participants had given their informed consent,
and the study was approved by the Research Ethics
Committee of the University of Lund.
Study design
At inclusion the patients were examined with chest
radiographs, spirometry, lung clearance of 99mTc-DTPA
and determination of serum angiotensin converting en-
zyme (SACE). In about half of the patients the same pro-
cedure was thus repeated at follow-up after 1 year. The
healthy smokers were examined with spirometry and
lung clearance of 99mTc-DTPA.
Lung function tests
Spirometry was performed with measurements of vital
capacity (VC) and forced expiratory volume in 1sec
(FEV1) in litres.
Lung clearance of 99mTc-DTPA was performed with
the patient inhaling an aerosol sitting in front of a gamma
camera interfaced with a computer system (3). There-
after, images of the lungs were obtained during 180min
with the patient in the supine position with the camera
beneath.Corrections were made for background radio-
activity and for the physical decay of 99mTc-DTPA (3). A
time^activity curve was generated from a region se-
lected over both lungs.The corrected curveswere sepa-
rately analysed by ¢tting a bi-exponential equation to
the experimental data as previously described (3). The
bi-exponential analysis showed an early fast and a slow
clearance course mathematically expressed as the rela-
tive amount of radioactivity cleared by the fast compo-
nent (fF), the half-life for the fast (t1/2F) and the slow
(t1/2S) components. The time-activity curve was also
¢tted to a mono-exponential equation in which clear-
ance was expressed as the half-life (t1/2) for the single
clearance component. The clearance of 99mTc-DTPA
was regarded as pathological if it was bi-exponential,
i.e. if the ¢t to the bi-exponential equation was signi¢-
cantlybetter than the ¢t to themono-exponential equa-
tion for which the reference value oft1/2 is 67718min.
SACE
The assay is based on an absorption spectrum shift oc-
curring upon hydrolysis of a synthetic substrate (10).
TABLE 2. Results of bi-exponential analysis of lung
clearance of 99mTc-DTPA at inclusion
Sarcoidosis
n¼11
Healthy smokers
n¼16
fF% 34719 57715
t1/2F 1374 1374
t1/2S 52712 83719
The fractionof 99mTc-DTPAclearedby the fast compo-
nent (fF) and the half-life for the fast (t1/2F) and slow
(t1/2S) clearance components are presented asmean7SD.
Signi¢cant di¡erences between the patients and the
healthy smokers aremarked ***¼Po0.001.
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FIG. 1. Individual values of the half-life for the slow clearance
component of 99mTc-DTPA (t1/2S) are shown for the sarcoid pa-
tients (expressed by a triangle) and for the healthy smokers (ex-
pressed by a circle).Medianvalues aremarked by a bar. t1/2Swas
signi¢cantly shorter inthe sarcoidpatients (Po0.001).
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in all patients participating in the follow-up.
Statisticalmethods
Data are mostly presented as means7standard devia-
tions, but inTable1medianvalues of some of thevariables
are givenbecause of clearly non-normal distribution.De-
viations from predicted values were analyzed with Stu-
dent’s t-test. Di¡erences between groups were investi-
gated with Wilcoxon’s rank sum test. The Wilcoxon
signed rank test was used for investigation of changes of
lung function results and SACEvaluesbetweeen the ¢rst
and follow-up examinations.For correlations Spearman’s
rank correlation test was used.Di¡erences with a prob-
ability level of Po0.05 are marked*, of Po0.01** and of
Po0.001***. The F-test was used to di¡erentiate be-
tween a mono- and a bi-exponential curve ¢t in the ana-
lysis of lung clearance of 99mTc-DTPA.The clearancewas
regarded as bi-exponential if the F-test indicated a signif-
icantly better ¢t by use of a bi-exponential than of a
mono-exponential equation (Po0.05).
Predicted normal values
Spirometric results are presented as percentage of the
predicted normal value. The reference values for these
parameters, and for t1/2 for the single clearance compo-
nent in patients with a mono-exponential lung clearance
of 99mTc-DTPA, were previously obtained from healthy
subjects (4,11).Values outside the 95% con¢dence interval
for healthy subjectswereregardedas abnormal.The nor-
mal range for SACEwas 25^80U/l.
RESULTS
Spirometric data at inclusion are shown inTable1.Two of
the patients and two healthy smokers had reduced VC.
Three patients had reduced FEV1. At follow-up VC and
FEV1were still reduced in one of the patients with initial
low values. FEV1 was then reduced also in another pa-
tient.Mean values of VC and FEV1 showed no signi¢cant
changes compared to initial values.
At inclusion in 11 patients with sarcoidosis and all 16
healthy smokers a bi-exponential curve ¢t was signi¢-
cantly better than a mono-exponential one.The results
from the bi-exponential analysis are shown inTable 2 and
Fig.1. In the patients there was no signi¢cant correlation
between the amount of their tobacco consumption and
either of fF, t1/2F or t1/2S. The patients and the healthy
smokers di¡ered with respect only to t1/2S (Po0.001)
(Table 2). t1/2S separated most sarcoid patients from
healthy smokers (Fig.1).
Four of the15 sarcoid patients showed a mono-expo-
nential clearance course with t1/2 57718min, i.e. withinthe normal range. When a bi-exponential analysis was
performedin these four patients, the F-testdidnot show
a signi¢cantly better ¢t.Their fF was 9, 8, 0 and 0%, t1/2F
was 8, 30, 0 and 0min, and t1/2Swas 46, 87, 57 and 57min.
At follow-up lung clearance ¢ndings were essentially
unchangedexcept in one stage I patient, who at inclusion
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clearance at follow-up had a normal mono-exponential
course.
At inclusion SACEwas 84725.Ten of the14 patients in
whom SACE was obtained showed a value above the
upper normal range. In the six patients reinvestigated,
at inclusion SACE was 99724 and at follow-up 50718,
i.e. therewas a signi¢cant improvement (Po0.05). At fol-
low-up all six patients showed a normal SACE value.
DISCUSSION
Wehavepreviously shown lungclearance of 99mTc-DTPA
to be abnormal, with either an abnormally short mono-
exponential tracer elimination or a bi-exponential clear-
ance, in well over 50% of non-smoking patients with in-
trathoracic sarcoidosis (3). Among thepatientswith a bi-
exponential clearance, those with the most advanced
radiologic stage had the fastest elimination rate of the
slow clearance component. In a previous study no corre-
lation in sarcoidosis between lung clearance results and
other lung function parameters was found (3). On the
other hand, Dusser et al. described a correlation be-
tween the clearance rate and some other function vari-
ables (6). In sarcoidosis a pathologic lung clearance may
keep abnormal at follow-up, or may restore to normal
either spontaneously or during treatment (5).
An increased pulmonary clearance of 99mTc-DTPA in
smokers was ¢rst described by Jones et al. (12). A bi-ex-
ponential clearance course is a common ¢nding in smo-
kers, when measurements are long enough, as was
observed in all individuals in the group of healthy smo-
kers (4). The relative amount of the tracer cleared by
the fast component, i.e. fF, correlates in healthy smokers
positively with cumulated tobacco consumption, and ne-
gatively with FEV1 (4). A positive correlation was also
found between the current tobacco consumption and
t1/2S (4). The changes of clearance induced by smoking
are reversiblewithin some days or weeks after cessation
of smoking (13).
The mechanisms resulting in an abnormal lung clear-
ance are still largely obscure. In sarcoidosis in£ammation
seems to be associatedwith increase in the permeability
of the epithelium (14). Surfactant dysfunction might in-
£uence the lung clearance of 99mTc-DTPA inboth sarcoi-
dosis and smoking (15,16). Alveolar instability, possibly
due to e.g. surfactant dysfunction, with a greater varia-
tion in alveolar volume than normally expectedhas been
proposed as another cause of pathologic lung clearance
in smokers (4). Indeed, ventilation with large tidal vo-
lumes has been shown to increase lung clearance (17).
However, there is no de¢nite answer as yet neither in
sarcoidosis, nor in smoking to the question of the exact
events behind a pathologic lung clearance, nor as to why
there are two principally di¡erent kinetic clearance pat-
terns.When comparing the bi-exponential lung clearance
curves in never-smoking sarcoid patients with the
healthy smokers, in sarcoidosis a smaller fF and a higher
clearance rate of the slow clearance component were
evident (3). In the present study t1/2S was shorter in the
smoking sarcoid patients than in the healthy smokers,
which is thus well in agreement with the previous study.
The lung function tests revealed no other signi¢cant dif-
ferences between the smoking patients and the healthy
smokers. Spirometry was on average normal in both
groups and thus did not indicate hyperin£ation.There is
no immediate explanation for the shorter t1/2S in sarcoi-
dosis.The di¡erence in t1/2Smight indicate othermechan-
isms behind a pathologic lung clearance of 99mTc-DTPA
in sarcoidosis than in smoking.
Only few patients were followed-up. Compared with
the results at inclusion no remarkable changeswere seen
at follow-up.
Interstitial lungdisease is sometimes detected from an
observation of increased clearance of 99mTc-DTPA in
lung scintigraphy (18).Clearance measurement has been
proposed to help in evaluation of disease activity and in
foreseeing ultimate lung function outcome (5,14,19).This
study indicates that the principle of clearance studies
may be useful also in smokers with sarcoidosis, and not
only in non-smoking patients. The long time for a com-
plete study of clearance of 99mTc-DTPA prevents its use
in clinical routine.One solution might be to focus on the
late part of the clearance curve. It appears that in smo-
kers the ¢rst part of the clearance curve is of less inter-
est, so that measurements could start late allowing a
short study time. Another potential solution might be
to use a tracermolecule that has a faster clearance from
the lungs than 99mTc-DTPA.
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